CervoMed initiated with a Buy at D. Boral Capital

D. Boral Capital analyst Jason Kolbert initiated coverage of CervoMed (CRVO) with a Buy rating and $34 price target CervoMed is developing neflamapimod for early-stage dementia with Lewy body patients, the analyst tells investors in a research note. The firm sees a “blockbuster opportunity,” noting neflamapimod targets the p38 alpha enzyme linked to neuroinflammation and early synaptic damage. Current clinical trials have shown promising improvements in cognitive and motor functions, particularly in early-stage DLB patients, contends D. Boral.